Emerging serotype III sequence type 17 group B streptococcus invasive infection in infants: The clinical characteristics and impacts on outcomes

Yi Kao, Ming Horng Tsai, Mei Yin Lai, Shih Ming Chu, Hsuan Rong Huang, Ming Chou Chiang, Ren Huei Fu, Jang Jih Lu, Jen Fu Hsu*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

33 Scopus citations

Abstract

Background: Group B Streptococcus (GBS) is an important pathogen that causes high mortality and morbidity in young infants. However, data on clinical manifestations between different GBS serotypes and correlation with molecular epidemiology are largely incomplete. The aim of this study was to determine the serotype distribution, antimicrobial resistance, clinical features and molecular characteristics of invasive GBS isolates recovered from Taiwanese infants. Methods: From 2003 to 2017, 182 non-duplicate GBS isolates that caused invasive disease in infants less than one year of age underwent serotyping, multilocus sequence typing (MLST) and antibiotic susceptibility testing. The clinical features of these infants with GBS disease were also reviewed. Results: Of the 182 patients with invasive GBS disease, 41 (22.5%) were early-onset disease, 121 (66.5%) were late-onset disease and 20 (11.0%) were late late-onset disease (> 90 days of age). All these patients were treated with effective antibiotics on time. Among them, 51 (28.0%) had meningitis, 29 (16.0%) had neurological complications, 12 (6.6%) died during hospitalization, and 15 (8.8%) out of 170 patients who survived had long-term neurological sequelae at discharge. Serotype III GBS strains accounted for 64.8%, followed by serotype Ia (18.1%) and Ib (8.2%). MLST analysis revealed 11 different sequence types among the 182 isolates and ST-17 was the most dominant sequence type (56.6%). The correlation between serotype III and ST17 was evident, as ST17 accounted for 87.3% of all serotype III isolates. There was an obvious increasing trend of type III/ST-17 GBS that caused invasive disease in infants. All isolates were susceptible to penicillin, cefotaxime, and vancomycin, while 68.1 and 65.9% were resistant to erythromycin and clindamycin, respectively. Conclusions: Despite timely and appropriate antibiotic treatment, a significant proportion of invasive GBS disease still inevitably causes adverse outcomes. Further study to explore preventive strategies and development of serotype-based vaccines will be necessary in the future.

Original languageEnglish
Article number538
JournalBMC Infectious Diseases
Volume19
Issue number1
DOIs
StatePublished - 19 06 2019

Bibliographical note

Publisher Copyright:
© 2019 The Author(s).

Keywords

  • Bacteremia
  • Drug resistance
  • Epidemiology
  • Group B streptococcus
  • Invasive streptococcal infection

Fingerprint

Dive into the research topics of 'Emerging serotype III sequence type 17 group B streptococcus invasive infection in infants: The clinical characteristics and impacts on outcomes'. Together they form a unique fingerprint.

Cite this